Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
about
Trastuzumab-containing regimens for metastatic breast cancerTrastuzumab containing regimens for early breast cancerTrastuzumab containing regimens for metastatic breast cancerEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerProgress and problems in the application of focused ultrasound for blood-brain barrier disruption.Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trialHER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.Clinical applications of a peptide-based vaccine for glioblastoma.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of deathBlood-brain barrier integrity and breast cancer metastasis to the brain.The molecular genomics of metastatic brain tumours.Role of efaproxiral in metastatic brain tumors.Surgical resection of brain metastases-impact on neurological outcome.Central nervous system metastasis from breast cancer.Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu statusImpact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapyBrain metastases free survival differs between breast cancer subtypes.Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse.Trastuzumab: triumphs and tribulations.CNS metastasis in primary breast cancer.Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 TrialLapatinib in metastatic breast cancer.Brain metastases: a medical neuro-oncology perspective.Ultrasound-mediated strategies in opening brain barriers for drug brain delivery.Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases.miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer.Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.Breast cancer brain metastases: Molecular subtype, treatment and survival.A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis.Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential.Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.
P2860
Q24194019-BFE0CF06-F786-4C9C-B732-1B624FA9CA45Q24200192-75DC509F-9F9F-449B-9126-8B8EC8DF8850Q24244565-B0626F1F-499C-4BA8-8CD0-49D112A62B46Q26824799-F6E36A56-063C-459B-BAB1-D2F553C06EC6Q30487878-9711538C-E5DE-483D-8A4F-83DBD41B0E83Q33279460-67425979-CCBF-45FA-8051-6506AAC0213CQ33517907-F55A8E3B-9CB3-431B-8503-6660083C95BDQ33668575-178ACEC2-B2FA-42C5-A3EF-4CCFBACB2E7BQ33715354-6BBAB707-8704-452F-AC49-312C02AF2F32Q33878643-5924395A-B199-4565-BAB2-363D8B9868A5Q33953465-D565DD61-87B2-4F71-829E-BDA971E6771EQ34022312-94D1D4BE-B856-40F7-87A8-7599346F7227Q34495518-78B4770E-7540-4643-8048-4F41A89D8BA1Q34499855-81E040F6-D7EB-4CEF-AE0E-3F30F69BE013Q34513604-5BE3220B-2115-451A-96D3-7D412020B92DQ34686390-26347CE1-A7DB-4367-A6AF-37C0105F6FFBQ34960132-F49FE211-11DC-47A6-BA8F-D2C6691090A0Q35605745-800BF93A-7544-4368-9EDB-C0897B08C426Q35653866-1848872B-B097-4DEF-BA92-25FA6A88DBAFQ35705221-511CD860-EE08-4D7B-9A7A-ACE839772637Q35739534-CDC23F07-337F-491D-9308-157EEEC56D75Q36420900-F05F633E-75B1-4A90-8C7D-0824717C59A6Q36832109-17CB58F8-032D-49C3-9166-83F20CC9E442Q37004668-40A5DF7E-4EF6-461A-BE5D-A47AE0489279Q37074153-41F05D26-1D66-4593-923A-A46EA6FAE3DBQ37321804-CB70445C-E8DD-4D36-BDB7-F960C3B589E7Q37622978-79CA97D0-75A4-4E31-BD72-8C30B4E9DB0AQ37724219-1E8E7869-3E49-4782-B448-B1C956535D1AQ38095513-5B5B8936-3930-401D-A5D0-642B105FCEE8Q38110196-D20242C2-0488-4282-878D-0FF41AEA5E8EQ38778447-6E628671-7F65-40BE-AB8F-661F3A1218B5Q38981296-134E5F1F-3BB2-45FF-B203-0BC7FEC642A8Q38996026-87460EDE-78BE-470F-BF2C-0E776A0AEE2DQ40081216-61B1EACC-0A8D-41C6-B962-EF6A7B370CB6Q42053919-0A492AB2-3F78-4C55-B4E0-2C9A92E71C53Q44176007-F2135582-4F27-4723-9C25-F83B4533ED68Q45757920-F0AEC4A3-5501-40F5-B164-46C4F718FD0BQ48363253-5FC9C7D6-C38F-4755-B2E2-F7908CF79521Q48380925-7F6832C7-F71C-40DB-A1DB-5BD6C538DAE9Q49544395-49208A0E-1C93-4463-A414-DA7D2B0D1A9B
P2860
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@en
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@nl
type
label
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@en
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@nl
prefLabel
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@en
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@nl
P2093
P2860
P356
P1433
P1476
Isolated central nervous syste ...... ine trastuzumab-based therapy.
@en
P2093
D J Slamon
G Lieberman
H J Burstein
P2860
P304
P356
10.1093/ANNONC/MDI371
P577
2005-09-08T00:00:00Z